

Lexaria Bioscience Corp.  
Form 8-K  
January 16, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 15, 2019**

**LEXARIA BIOSCIENCE CORP.**  
**(Exact Name of Registrant as Specified in its Charter)**

<b>Nevada</b> <b>(State or other jurisdiction</b>	<b>000-52138</b> <b>(Commission</b>	<b>20-2000871</b> <b>(I.R.S. Employer</b>
<b>of incorporation)</b>	<b>File Number)</b>	<b>Identification No.)</b>

**156 Valleyview Road**

**Kelowna, British Columbia, V1X 3M4**

**Canada**

**(Address of principal executive offices and zip code)**

**(250) 765-6424**

**(Registrant's telephone number, including area code)**

Edgar Filing: Lexaria Bioscience Corp. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ..

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ..

**Item 7.01 Regulation FD Disclosure.**

On January 15, 2019, Lexaria Bioscience Corp. issued a press release announcing a partnership with Altria Ventures Inc., a subsidiary of Altria Group, Inc., to fund research and development of DehydraTECH™ technology for oral nicotine, a copy of which is attached as Exhibit 99.1 and incorporated by reference in this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit**

<b>No.</b>	<b>Description</b>
<u>99.1</u>	<u>Press release of Lexaria Bioscience Corp., dated January 15, 2019, announcing the partnership with a subsidiary of Altria Group, Inc. to fund research and development of DehydraTECH™ technology for oral nicotine.</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LEXARIA BIOSCIENCE CORP**

Date: January 16, 2019

By: */s/ Chris Bunka*

Name: Chris Bunka

Title: Chief Executive Officer